Philippines Next-Generation Sequencing (NGS) Market (2026-2036)
The Philippines next generation sequencing market is projected to reach USD 177.96 million by 2036 from an estimated USD 54.80 million in 2026, growing at a CAGR of 12.5% during the forecast period from 2026 to 2036. The market stood at USD 48.60 million in 2025.
- Published
- Sep 2026
- Pages
- 138
- Format
- PDF + Excel
- Report ID
- MR-2175
- Base year
- 2025
- 2025 · BASELINE
- $48.6M
- 2036
- $178.0M
- CAGR 2026–2036
- 12.5%
2025 baseline · 2026–2036 forecast at 12.5% CAGR · hover a bar for the value
Key highlights
The Philippines next generation sequencing market is projected to reach USD 177.96 million by 2036, growing at a CAGR of 12.5% during 2026 to 2036, a trajectory built on a funded population wide genetic screening programme, expanding PhilHealth coverage of targeted cancer therapy, and a cancer burden weighted toward tumour types that depend on molecular characterisation.
Newborn bloodspot screening was integrated into the Philippine public health system by Republic Act 9288 in 2004, having first been introduced across 24 private and government hospitals in 1996. The Expanded Newborn Screening panel now covers 28 conditions using tandem mass spectrometry, and PhilHealth reimburses the test at PHP 2,950 under the Newborn Care Package, a sum that fully covers the cost at most accredited facilities.
A positive newborn screen identifies the affected metabolic pathway but not the causative variant, and confirmation increasingly depends on sequencing. This confirmatory tier, rather than the screening tier itself, is where sequencing demand in this market is concentrated, since the screening panel is performed by tandem mass spectrometry.
According to IARC GLOBOCAN, lung cancer recorded 23,728 new cases and 20,953 deaths in the Philippines in 2022, making it the second most common malignancy and the leading cause of cancer mortality in the country, with more than 70% of cases diagnosed at stage III or IV according to the hospital based CARE PH registry project.
PhilHealth expanded its Z Benefit Package in 2024 to cover targeted therapy for breast cancer at up to PHP 1 million per patient annually, roughly USD 18,000, while Circular 2025 0014 issued under Board Resolution No. 3018 s.2025 established benefit packages for selected outpatient cancer screening.
Only locally established Filipino companies may hold the Licence to Operate required to register and distribute medical devices in the country, so a foreign sequencing platform manufacturer cannot hold its own market authorisation and must work through a Filipino entity that holds the licence in its own name.
Suppliers already approved by another ASEAN national regulator may apply for Abridged Processing, submitting the same technical dossier lodged with the reference agency, which shortens the registration timeline relative to a market requiring a fully independent submission.
Analysis and interpretation software used in patient management is expressly regulated as Software as a Medical Device under Administrative Order 2018 0002, bringing the bioinformatics segment inside the registration framework in a way not seen across several comparable regional markets.
Roche launched its AXELIOS 1 sequencing platform commercially on 29 June 2026, built on sequencing by expansion chemistry acquired with Stratos, reaching clinical buyers through diagnostics relationships the company already holds across Philippine hospital laboratories.
Illumina, Inc. and Thermo Fisher Scientific Inc. together with QIAGEN N.V. hold the leading positions in this market, supported by Illumina's clinical sequencing consumables growing 20% excluding China for two consecutive quarters and by Thermo Fisher's automated, sample to result Ion Torrent Genexus workflow designed for deployment in regional and community hospitals.
Report summary
| Particulars | Details |
|---|---|
| Forecast Period | 2026–2036 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Historical Year | 2024 |
| CAGR (Value) | 12.5% |
| Format | PDF, Excel & Cloud Portal · 138 pages |
| Market Size (Value) in 2026 | USD 54.80 Million |
| Market Size (Value) in 2036 | USD 177.96 Million |
| Segments Covered | By Offering: Sample Preparation (Kits & Reagents, NGS Workstations); Sequencing (NGS Systems, Consumables, Services); Data Analysis/Bioinformatics (Software, NGS Informatics Services); Commercial Sequencing/Outsourced Services (WGS, WES, Targeted, RNA, Other Services). By Application: Research & Other (Drug Discovery, Agriculture & Animal Research, Other Applications); Clinical (Oncology, Reproductive Health, Infectious Diseases, Rare Diseases, Other Clinical Applications). By End User: Pharmaceutical & Biotechnology Companies; Hospitals, Clinical & Reference Laboratories; Academic & Research Institutes; Other End Users |
| Key Companies | Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), F. Hoffmann La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), Revvity, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies plc (U.K.), MGI Tech Co., Ltd. (China), BGI Genomics Co., Ltd. (China), Eurofins Scientific SE (Luxembourg), Novogene Co., Ltd. (China) |
| Primary Reference Sources | Food and Drug Administration, Philippines; PhilHealth circulars and board resolutions; Department of Health issuances; Newborn Screening Reference Center, National Institutes of Health, University of the Philippines Manila; Philippine Genome Center; Department of Science and Technology and DOST PCHRD; IARC GLOBOCAN; World Health Organization; CARE PH hospital based registry; company annual reports, investor presentations, and earniNGS call transcripts of sequencing platform manufacturers and commercial service providers |
Report overview
Segments covered: offering, application, end user.
Clinical applications account for the largest share of market value through most of the forecast period, a position that reflects a funded national newborn screening programme reaching effectively every newborn in the country, while oncology represents the fastest growing clinical application as the concentration of the Philippine cancer burden in tumour types with strong molecular testing requirements pushes sequencing deeper into cancer care.
Next generation sequencing comprises a group of high throughput technologies that determine the order of nucleotides across many DNA or RNA fragments in parallel, permitting the interrogation of targeted gene panels, whole exomes, or whole genomes within a single workflow. As defined in this study, the Philippines NGS market comprises revenue generated from the sale of sample preparation products, sequencing systems and consumables, data analysis software and informatics services, and commercial sequencing services to organisations operating within the Philippines, regardless of where the supplying entity is located, including instances where the physical sequencing is performed elsewhere under an outsourced arrangement.
Two features set this market apart from comparable geographies covered in this series. The country operates a funded, population scale genetic screening programme, described by published assessment as the most successful population based genetic screening effort in the Philippines, and no comparable market in this series reimburses genetic screening at this scale. At the same time, the Philippines has no national cancer registry. Only four subnational registries operate, sampling Manila, Rizal, Cebu, and Davao, and global cancer catalogues combine this subnational data with projections from neighbouring Southeast Asian countries using statistical modelling, so incidence figures used throughout this market are derived rather than directly counted.
The Philippine health system operates under near universal insurance coverage. The Universal Health Care Act, Republic Act 11223, ratified in July 2018, automatically enrols all Filipinos in the National Health Insurance Program, with coverage approaching 90% of the population, up from roughly 50% when PhilHealth was created in 1995. Yet access to advanced diagnostics remains uneven. Diagnostic and treatment facilities are concentrated in urban centres, and molecular testing is seldom available in regional hospitals, so clinical indication does not reliably translate into testing volume across the archipelago.
Demand in this market is increasingly shaped by the economics and structure of reimbursement rather than by research funding alone. PhilHealth already pays for population scale genetic screening through the newborn programme and has extended coverage to targeted cancer therapy, yet the case rate system continues to cover diagnostics only partially, so molecular testing that determines eligibility for a reimbursed therapy is not itself consistently funded. This gap, closing one coverage decision at a time rather than requiring an entirely new funding route, is expected to shape how quickly clinical sequencing volume grows through 2036.
Market dynamics
8 factors across 3 forcesThe Funded Newborn Screening Programme and Its Confirmatory Tier
The national newborn screening programme is the largest single source of genetic testing volume in the Philippines and the only population scale genetic screening effort in this series that carries reimbursement. Screening was integrated into the public health system by Republic Act 9288 in 2004, the Expanded panel now covers 28 conditions using tandem mass spectrometry, and PhilHealth pays PHP 2,950 under the Newborn Care Package, fully covering the cost at most accredited facilities. A positive screen triggers confirmatory testing rather than a diagnosis, and for metabolic, hormonal, and haemoglobin disorders that confirmation increasingly requires identifying the causative variant, since the variant determines prognosis, treatment selection, and recurrence risk for the family.
PhilHealth Funding of Targeted Cancer Therapy
PhilHealth has committed to funding targeted cancer treatment at a level that makes the molecular test establishing eligibility commercially material. The Z Benefit Package, expanded in 2024, now covers targeted therapy for breast cancer at up to PHP 1 million per patient annually, approximately USD 18,000, and Circular 2025 0014 established benefit packages for selected outpatient cancer screening. Because the payer already funds the therapy, closing the coverage gap on the diagnostic that selects the right patient requires one decision within an existing scheme rather than the creation of an entirely new funding route.
Cancer Burden Concentrated in Tumour Types Requiring Molecular Testing
The Philippine cancer burden is weighted toward the tumour type with the strongest molecular testing requirement. Lung cancer recorded 23,728 new cases and 20,953 deaths in 2022 according to IARC GLOBOCAN, making it the second most common malignancy and the leading cause of cancer mortality, with more than 70% of cases diagnosed at stage III or IV according to CARE PH. Lung cancer treatment depends on molecular characterisation more directly than any other common solid tumour, because identifying driver alterations determines which targeted agents can be used at all.
Table of contents
10 chapters · 185 sections · 138 pages · click to expandSegmental analysis
| Segment | Largest share (2026) | Fastest growth (2026–2036) |
|---|---|---|
| By Offering | Sequencing | Data Analysis/Bioinformatics |
| By Application | Application: Clinical | Oncology |
| By End User | Hospitals and Clinical Laboratories | — |
By Offering
- Sequencing Leads in 2026, Data Analysis/Bioinformatics Grows Fastest
- Data Analysis/Bioinformatics Grows Fastest
- The market is segmented into sample preparation, sequencing, data analysis/bioinformatics, and commercial sequencing/outsourced services.
- The sequencing segment accounts for the largest share of the market.
- The data analysis/bioinformatics segment is expected to register the highest growth, indicating the express regulation of clinical analysis software as a medical device and the requirement for validated clinical reporting.
By Application
- Clinical Applications Dominate in 2026, Oncology Grows Fastest
- By Application: Clinical Applications Dominate in 2026, Oncology Grows Fastest
- The market is segmented into research & other applications and clinical applications.
- Clinical applications hold the largest share of the market driven by the absence of a publicly funded population research sequencing programme of the kind operating in several comparable markets.
- Within clinical applications, reproductive health holds the largest share of the market, funded directly by patients, while oncology is projected to register the highest growth.
By End User
- Hospitals and Clinical Laboratories Lead in 2026
- By End User: Hospitals and Clinical Laboratories Lead in 2026
- The market is segmented into pharmaceutical & biotechnology companies, hospitals, clinical & reference laboratories, academic & research institutes, and other end users.
- Hospitals, clinical & reference laboratories account for the largest share of the market.
- Other end users, comprising principally agricultural, aquaculture, and plantation organisations grow independently of clinical funding and access conditions.
Competitive landscape
The Philippines next generation sequencing market is consolidated and led by international suppliers, none of which manufactures within the country. Some of the prominent players operating in this market include Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), F. Hoffmann La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies plc (U.K.), MGI Tech Co., Ltd. (China), BGI Genomics Co., Ltd. (China), Eurofins Scientific SE (Luxembourg), and Novogene Co., Ltd. (China).
- —
Roche launched the AXELIOS 1 sequencing platform commercially on 29 June 2026, built on sequencing by expansion chemistry acquired with Stratos, reporting approximately 99% concordance with the leading technology across 118 tumour normal pairs.
- —
Illumina completed its acquisition of SomaLogic in January 2026, extending its position from genomics into proteomics.
- —
MGI Tech announced the acquisition of STOmics and CycloneSEQ in March 2026, bringing spatial multiomics and long read nanopore sequencing capability fully in house.
- —
QIAGEN completed its acquisition of Parse Biosciences in December 2025, tracking ahead of its USD 40 million sales target for 2026 and expanding into single cell analysis.
- —
Thermo Fisher's Ion Torrent Oncomine Dx Target Test received United States approval as a companion diagnostic, described as widely accessible on the strength of broad reimbursement coverage.
- —
Agilent received United States approval for expanded use of its PD L1 IHC 22C3 pharmDx assay on the Dako Omnis platform across additional tumour types during 2026.
- Illumina, Inc. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- QIAGEN N.V. · Netherlands
- F. Hoffmann La Roche Ltd. · Switzerland
- Agilent Technologies, Inc. (U.S.)
- Revvity, Inc. (U.S.)
- Pacific Biosciences of California, Inc. (U.S.)
- Danaher Corporation (U.S.)
- Oxford Nanopore Technologies plc (U.K.)
- MGI Tech Co., Ltd. · China
- BGI Genomics Co., Ltd. · China
- Eurofins Scientific SE · Luxembourg
- Novogene Co., Ltd. · China
Frequently asked questions
The Philippines next generation sequencing market size is estimated at USD 54.80 million in 2026.
Cite this report
Meticulous Research. (2026). Philippines Next-Generation Sequencing (NGS) Market - Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MR-2175). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/philippines-next-generation-sequencing-market-6858